Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Drugmaker BridgeBio Pharma's experimental oral drug infigratinib has been granted priority review by the U.S. Food and Drug Administration (FDA) for treating achondroplasia, the most common form of dwarfism in children. The FDA has set February 4, 2027, as the target decision date. A late-stage study showed children tr
BridgeBio announced that the FDA has accepted its New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia, granting it Priority Review. The target action date is February 4, 2027. If approved, it would be the first oral targeted therapeutic option for this condition.